Guy Richards

Prof. Guy Richards

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2011 in Journal of Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
GRGuy Richards
Guy Richards
HLHoward Levy
Howard Levy
PLPierre-Francois Laterre
Pierre-Francois Laterre
CFCharles Feldman
Charles Feldman
BWBrad Woodward
Brad Woodward
RQRebecca L. Qualy
Rebecca L. Qualy
Background: Patients with community-acquired pneumonia (CAP) comprised 35.6% of the overall phase 3 Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study and 33.1% of the placebo arm. We investigated the use of CURB-65, the Pneumonia Severity Index (PSI), and Acute Physiology and Chronic Health Evaluation II (APACHE II) prediction scores to identify the CAP population from the PROWESS placebo arm at the greatest mortality risk. Methods: Patients were classified as having CAP if the lung was the primary infection site and the patient originated from home. The abilities of CURB-65, PSI, and APACHE II scores to determine the 28-day and in-hospital mortality were compared using receiver operator characteristic (ROC) curves and the associated areas under the curve. Results: PROWESS enrolled 278 patients with CAP in the placebo arm. The areas under the ROC curves for PSI = 5, CURB-65 ≥3, and APACHE II ≥25 for predicting 28-day (c = 0.65, 0.66, and 0.64, respectively) and in-hospital mortality (c = 0.65, 0.65, and 0.64, respectively) were not statistically different from each other. The 28-day mortality of patients with a PSI score of 5, CURB-65 ≥3, and APACHE II ≥25 was 41.6%, 37.9%, and 43.5%, respectively. Conclusions: Despite early diagnosis and appropriate antibiotic therapy, conventionally treated CAP with PSI = 5, CURB-65 ≥3, or APACHE II ≥25 has an unacceptably high mortality. In this study, PSI, CURB-65, and APACHE II scoring systems perform similarly in predicting the 28-day and in-hospital mortality; however, differences in the categorization of severe CAP were observed and there was a significant mortality in patients with a CURB-65 <3 and PSI <5.

1 February 2018 in Journal of Critical Care
Verified
Journal Article
Closed access
JJJuan Ignacio Silesky Jiménez
Juan Ignacio Silesky Jiménez
JMJorge Luis Hidalgo Marroquin
Jorge Luis Hidalgo Marroquin
GRGuy Richards
Guy Richards
PAPravin Amin
Pravin Amin

1 August 2021 in Journal of Infection
Verified
Journal Article
Closed access
JVJacqui Venturas
Jacqui Venturas
JZJarrod Zamparini
Jarrod Zamparini
ESErica Shaddock
Erica Shaddock
SSSarah Stacey
Sarah Stacey
LMLyle Murray
Lyle Murray
CFCharles Feldman
Charles Feldman

1 September 2018 in Indian Heart Journal
Verified
Journal Article
Open access
ALAbdullah Ebrahim Laher
Abdullah Ebrahim Laher
GRGuy Richards
Guy Richards
Pulmonary embolism (PE) is a potentially life threatening clinical condition that is fairly non-specific in presentation. Massive pulmonary embolism (PE) without cardiac arrest has been associated with a mortality rate of 30%. However, when cardiac arrest ensues, mortality may be as high as 95%. Since outcomes of cardiac arrest following PE are generally dismal, any available potentially life-saving measure must be instituted when the diagnosis of PE is suspected. Despite a lack of randomized controlled trials guiding the management of suspected PE in the cardiac arrest victim, thrombolysis and other therapies have been associated with good outcomes in the handful of published case reports and other small studies.

15 September 2014 in Critical Care
Verified
Journal Article
Open access
PDF file
GRGuy Richards
Guy Richards
Adrian John MBCHB, MMedAdrian John MBCHB, MMed
Adrian John MBCHB, MMed
Numerous factors interfere with the ability to achieve optimal pharmacokinetic and pharmacodynamic targets and this has been associated with greater mortality and lower cure rates. The recent study by Zoller and colleagues examining linezolid levels in critically ill patients emphasises this point. Their study is unique in the description of the intra-patient and inter-patient variability that occurs and in the degree to which therapy is inadequate; 63% of patients had insufficient levels and only 17% maintained optimal trough values (between 2 and 10 mg/l) throughout the 4 study days. Precisely why this result occurred is uncertain because albumin levels, free linezolid pharmacokinetics and the presence of augmented renal clearance were not recorded in the current study. The extent of this variability makes the case for therapeutic drug monitoring since an area under the inhibitory curve greater than 80 to 120 and the time above the minimum inhibitory concentration over the entire dosing interval strongly correlate with linezolid treatment efficacy. Accordingly, therapeutic drug monitoring where available or, if not available, alternative approaches to drug delivery such as continuous infusion or a dose increase - but particularly the former - may be the answer.

1 August 2018 in Journal of Critical Care
Verified
Journal Article
Closed access
DKDilip R. Karnad
Dilip R. Karnad
GRGuy Richards
Guy Richards
GSGisele Sampaio Silva
Gisele Sampaio Silva
PAPravin Amin
Pravin Amin